Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Alpha glucosidase inhibitor voglibose can prevent pioglitazone-induced body weight gain in Type 2 diabetic patients.

Literature DB >> 18507653

Alpha glucosidase inhibitor voglibose can prevent pioglitazone-induced body weight gain in Type 2 diabetic patients.

Mayumi Negishi, Kenju Shimomura, Peter Proks, Yohnosuke Shimomura, Masatomo Mori.

Abstract

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 2008 PMID： 18507653 PMCID： PMC2492932 DOI： 10.1111/j.1365-2125.2008.03216.x

Source DB: PubMed Journal: Br J Clin Pharmacol ISSN： 0306-5251 Impact factor: 4.335

× No keyword cloud information.

10 in total

1. Efficacy of troglitazone on body fat distribution in type 2 diabetes.

Authors: S Akazawa; F Sun; M Ito; E Kawasaki; K Eguchi
Journal: Diabetes Care Date: 2000-08 Impact factor: 19.112

Review 2. Miglitol, a new alpha-glucosidase inhibitor.

Authors: J P Sels; M S Huijberts; B H Wolffenbuttel
Journal: Expert Opin Pharmacother Date: 1999-11 Impact factor: 3.889

3. Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes.

Authors: I E Kelly; T S Han; K Walsh; M E Lean
Journal: Diabetes Care Date: 1999-02 Impact factor: 19.112

4. Effect of pioglitazone on body composition and energy expenditure: a randomized controlled trial.

Authors: Steven R Smith; Lilian De Jonge; Julia Volaufova; Yinmei Li; Hui Xie; George A Bray
Journal: Metabolism Date: 2005-01 Impact factor: 8.694

5. alpha-Glucosidase inhibitors prevent diet-induced increases in intestinal sugar transport in diabetic mice.

Authors: Donatella M Casirola; Ronaldo P Ferraris
Journal: Metabolism Date: 2006-06 Impact factor: 8.694

6. Effect of troglitazone on body fat distribution in type 2 diabetic patients.

Authors: Y Mori; Y Murakawa; K Okada; H Horikoshi; J Yokoyama; N Tajima; Y Ikeda
Journal: Diabetes Care Date: 1999-06 Impact factor: 19.112

7. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone.

Authors: Brent A Neuschwander-Tetri; Elizabeth M Brunt; Kent R Wehmeier; Dana Oliver; Bruce R Bacon
Journal: Hepatology Date: 2003-10 Impact factor: 17.425

8. Effects of alpha-glucosidase inhibitor (acarbose) combined with sulfonylurea or sulfonylurea and metformin in treatment of non-insulin-dependent diabetes mellitus.

Authors: S Vannasaeng; S Ploybutr; W Nitiyanant; T Peerapatdit; A Vichayanrat
Journal: J Med Assoc Thai Date: 1995-11

Review 9. Acarbose. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential.

Authors: S P Clissold; C Edwards
Journal: Drugs Date: 1988-03 Impact factor: 9.546

10. Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes.

Authors: Mandeep Bajaj; Swangjit Suraamornkul; Thongchai Pratipanawatr; Lou J Hardies; Wilailak Pratipanawatr; Leonard Glass; Eugenio Cersosimo; Yoshinori Miyazaki; Ralph A DeFronzo
Journal: Diabetes Date: 2003-06 Impact factor: 9.461

10 in total

4 in total

1. Green tea extract with polyethylene glycol-3350 reduces body weight and improves glucose tolerance in db/db and high-fat diet mice.

Authors: Jae-Hyung Park; Yoon Jung Choi; Yong Woon Kim; Sang Pyo Kim; Ho-Chan Cho; Shinbyoung Ahn; Ki-Cheor Bae; Seung-Soon Im; Jae-Hoon Bae; Dae-Kyu Song
Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2013-04-27 Impact factor: 3.000